Changchun BCHT Biotechnology Co. (SHA:688276)
China
· Delayed Price · Currency is CNY 19.00
+0.25 (1.33%)
Mar 10, 2026, 3:00 PM CST
SHA:688276 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 591.81 | 1,229 | 1,825 | 1,071 | 1,201 | Upgrade
|
| Other Revenue | - | - | 0.14 | 0.05 | 0.75 | Upgrade
|
| Revenue | 591.81 | 1,229 | 1,825 | 1,071 | 1,202 | Upgrade
|
| Revenue Growth (YoY) | -51.85% | -32.64% | 70.30% | -10.86% | -16.61% | Upgrade
|
| Cost of Revenue | - | 206.06 | 210.35 | 181.93 | 228.56 | Upgrade
|
| Gross Profit | 591.81 | 1,023 | 1,614 | 889.52 | 973.47 | Upgrade
|
| Selling, General & Admin | - | 582.83 | 800.93 | 552.73 | 555.93 | Upgrade
|
| Research & Development | - | 156.14 | 198.07 | 133.53 | 156.76 | Upgrade
|
| Other Operating Expenses | 954.37 | 9.83 | 13.04 | 9.7 | 10.58 | Upgrade
|
| Operating Expenses | 954.37 | 772.28 | 1,072 | 729.59 | 734.04 | Upgrade
|
| Operating Income | -362.56 | 250.74 | 541.96 | 159.93 | 239.43 | Upgrade
|
| Interest Expense | - | -1.52 | -0.7 | - | -0.33 | Upgrade
|
| Interest & Investment Income | - | 4.6 | 12.44 | 18.4 | 11.78 | Upgrade
|
| Earnings From Equity Investments | - | -0.44 | 0.69 | 0.31 | -1.02 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.87 | 0.67 | 1.86 | -0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | 19.37 | -0.25 | -0.21 | -0.15 | -0.16 | Upgrade
|
| EBT Excluding Unusual Items | -343.19 | 254 | 554.85 | 180.35 | 249.55 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -2.55 | -0.9 | -0.73 | -2.19 | Upgrade
|
| Asset Writedown | - | -0.78 | - | - | - | Upgrade
|
| Other Unusual Items | - | 4.41 | 2.91 | 18.07 | 14.2 | Upgrade
|
| Pretax Income | -343.19 | 255.77 | 563.76 | 197.69 | 261.57 | Upgrade
|
| Income Tax Expense | -71.12 | 23.68 | 62.75 | 16.16 | 18.01 | Upgrade
|
| Net Income | -272.07 | 232.09 | 501.01 | 181.54 | 243.55 | Upgrade
|
| Net Income to Common | -272.07 | 232.09 | 501.01 | 181.54 | 243.55 | Upgrade
|
| Net Income Growth | - | -53.67% | 175.98% | -25.46% | -41.77% | Upgrade
|
| Shares Outstanding (Basic) | 412 | 414 | 414 | 413 | 393 | Upgrade
|
| Shares Outstanding (Diluted) | 412 | 414 | 414 | 413 | 393 | Upgrade
|
| Shares Change (YoY) | -0.54% | 0.10% | 0.36% | 5.03% | 7.07% | Upgrade
|
| EPS (Basic) | -0.66 | 0.56 | 1.21 | 0.44 | 0.62 | Upgrade
|
| EPS (Diluted) | -0.66 | 0.56 | 1.21 | 0.44 | 0.62 | Upgrade
|
| EPS Growth | - | -53.72% | 175.00% | -29.03% | -45.61% | Upgrade
|
| Free Cash Flow | - | -135.92 | -215.46 | -250.91 | -492.58 | Upgrade
|
| Free Cash Flow Per Share | - | -0.33 | -0.52 | -0.61 | -1.25 | Upgrade
|
| Dividend Per Share | - | 0.169 | 0.150 | 0.150 | 0.100 | Upgrade
|
| Dividend Growth | - | 12.67% | - | 50.00% | - | Upgrade
|
| Gross Margin | 100.00% | 83.23% | 88.47% | 83.02% | 80.98% | Upgrade
|
| Operating Margin | -61.26% | 20.40% | 29.70% | 14.93% | 19.92% | Upgrade
|
| Profit Margin | -45.97% | 18.88% | 27.46% | 16.94% | 20.26% | Upgrade
|
| Free Cash Flow Margin | - | -11.06% | -11.81% | -23.42% | -40.98% | Upgrade
|
| EBITDA | -258.38 | 354.92 | 633.94 | 230.87 | 307.76 | Upgrade
|
| EBITDA Margin | -43.66% | 28.88% | 34.74% | 21.55% | 25.60% | Upgrade
|
| D&A For EBITDA | 104.18 | 104.18 | 91.99 | 70.94 | 68.34 | Upgrade
|
| EBIT | -362.56 | 250.74 | 541.96 | 159.93 | 239.43 | Upgrade
|
| EBIT Margin | -61.26% | 20.40% | 29.70% | 14.93% | 19.92% | Upgrade
|
| Effective Tax Rate | - | 9.26% | 11.13% | 8.17% | 6.89% | Upgrade
|
| Revenue as Reported | - | 1,229 | 1,825 | 1,071 | 1,202 | Upgrade
|
| Advertising Expenses | - | 435.57 | 568.76 | 371.28 | 411.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.